Want to see INKT full AI Analyst Report?
Top Page
MiNK Therapeutics
(NASDAQ:INKT)
Select Model
Select Model
Rating:49Neutral
Price Target:
$11.00
▼(-3.34% Downside)
Action:Reiterated
Date:08/17/26
The score is held down primarily by weak financial performance (no revenue, ongoing losses, negative equity) and especially high cash-flow risk driven by the extremely large TTM operating cash outflow. Offsetting this, the latest earnings call reflected credible execution progress toward randomized clinical data and improving loss metrics, while technical indicators are broadly neutral and valuation offers limited support due to negative earnings and no dividend.
Positive Factors
Off-the-shelf iNKT platform
An inventory-based, allogeneic product could simplify deployment, reduce manufacturing complexity, and broaden access versus personalized cell therapies. The platform's use in austere settings may support scalability across cancer and serious-disease indications.
Negative Factors
No revenue and persistent losses
MiNK has not established commercial revenue and remains materially loss-making, with negative gross profit across periods. Without an approved product or recurring inflows, future progress depends on successful clinical development and eventual external financing.
Read all positive and negative factors
Positive Factors
Negative Factors
Off-the-shelf iNKT platform
An inventory-based, allogeneic product could simplify deployment, reduce manufacturing complexity, and broaden access versus personalized cell therapies. The platform's use in austere settings may support scalability across cancer and serious-disease indications.
Read all positive factors
MiNK Therapeutics (INKT) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$60.16M
Dividend YieldN/A
Average Volume (3M)39.56K
Price to Earnings (P/E)―
Beta (1Y)0.04
Revenue GrowthN/A
EPS Growth15.65%
CountryUS
Employees15
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.39
Shares Outstanding5,103,002
10 Day Avg. Volume31,712
30 Day Avg. Volume39,559
Financial Highlights & Ratios
PEG Ratio-3.68
Price to Book (P/B)-3.35
Price to Sales (P/S)0.00
P/FCF Ratio-8.04
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$35.00Price Target Upside207.56% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-2.75
Revenue Forecast (FY)N/A
MiNK Therapeutics Business Overview & Revenue Model
Company Description
MiNK Therapeutics, Inc. is a biopharmaceutical firm currently undergoing clinical trials. Its primary focus is on the identification, advancement, and market introduction of innovative invariant natural killer T (iNKT) cell therapies. These treatm...
How the Company Makes Money
null...
MiNK Therapeutics Earnings Call Summary
Earnings Call Date:Aug 13, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Nov 13, 2026
Earnings Call Sentiment Positive
The call delivered several important operational and scientific advances: initiation and operationalization of a randomized Phase 2 ARDS study (including dosing in an active conflict zone), positive early clinical and mechanistic signals from run-in patients, launch of a paid international named patient access program (Brazil), and improved quarter-over-quarter loss metrics. However, early clinical data are limited and non-randomized, operating cash usage increased (cash modestly declined q/q to $8.8M), and enrollment/regulatory risks and funding needs remain. On balance, the call emphasized meaningful progress on execution and translational rationale while acknowledging remaining proof-of-concept and financing risks.Positive Updates
Initiation of Randomized Phase 2 Study (C-1300-02)
MiNK initiated dosing in a randomized Phase 2 study of agenT-797 versus placebo in adult patients with acute lung injury/ARDS (study C-1300-02). The trial opened in Lviv, Ukraine, and US site activation is underway with plans to report additional randomized data in early 2027 (preliminary readouts expected in H1 2027). The company is preparing an FDA meeting to pursue a seamless transition from randomized Phase 2 into a confirmatory Phase 3.
Negative Updates
Early Clinical Data Limited and Non-Randomized
The promising day-28 observations derive from a small, non-randomized run-in (planned ~10 patients; publicized details from two patients). Management cautioned against overinterpretation — randomized comparative evidence is required to establish efficacy, and attribution to agenT-797 remains uncertain until larger randomized data are available.
Read all updates
Q2-2026 Updates
Positive
Negative
Initiation of Randomized Phase 2 Study (C-1300-02)
MiNK initiated dosing in a randomized Phase 2 study of agenT-797 versus placebo in adult patients with acute lung injury/ARDS (study C-1300-02). The trial opened in Lviv, Ukraine, and US site activation is underway with plans to report additional randomized data in early 2027 (preliminary readouts expected in H1 2027). The company is preparing an FDA meeting to pursue a seamless transition from randomized Phase 2 into a confirmatory Phase 3.
Read all positive updates
Company Guidance
The company guided that enrollment in the randomized Phase 2 C-1300-02 (which includes a ~10‑patient run‑in) is underway in Lviv with U.S. sites activating in September and an expected preliminary randomized readout in early 2027 / the first half of 2027; management cited a target enrollment pace of roughly 4–8 patients per site per month once sites are fully active, plans to seek an FDA meeting in the coming weeks to enable a seamless Phase 3 and will perform a Phase 2 sample‑size re‑estimation tied to a 28‑day mortality primary endpoint. Financial guidance and metrics disclosed: cash and cash equivalents of $8.8M (down from $9.5M at 3/31/26 and up from $3.4M at year‑end 2025), Q2 net loss of $3.1M or $0.62/share (versus $4.2M or $1.06/share in Q2 2025), H1 net loss $5.9M or $1.20/share (versus $7.0M or $1.76/share prior year), and cash used in operations of $2.1M this quarter (vs. $1.6M a year ago) driven by operationalizing the randomized study; they also launched a paid named‑patient program in Brazil (first patients treated after quarter close) and noted prior oncology data showing a 77% disease control rate in PD‑1‑refractory gastroesophageal cancer.MiNK Therapeutics Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
18
Very Negative
Cash Flow
8
Very Negative
| Breakdown | TTM | Mar 2026 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -154.35K | -181.75K | -215.44K | -204.62K | -121.75K | -77.96K |
| EBITDA | -11.29M | -12.31M | -10.57M | -22.25M | -27.87M | -27.70M |
| Net Income | -11.36M | -12.49M | -10.78M | -22.46M | -27.99M | -30.21M |
Balance Sheet | ||||||
| Total Assets | 9.62M | 14.24M | 5.72M | 4.55M | 21.47M | 40.24M |
| Cash, Cash Equivalents and Short-Term Investments | 8.81M | 13.36M | 4.58M | 3.37M | 19.64M | 38.89M |
| Total Debt | 0.00 | 5.18M | 4.92M | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 23.64M | 28.47M | 25.31M | 22.61M | 21.87M | 16.47M |
| Stockholders Equity | -14.03M | -14.23M | -19.59M | -18.06M | -401.30K | 23.78M |
Cash Flow | ||||||
| Free Cash Flow | -2.09B | -5.93M | -9.56M | -15.84M | -19.12M | -13.08M |
| Operating Cash Flow | -2.09B | -5.93M | -9.56M | -15.76M | -18.87M | -12.83M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | -73.56K | -250.05K | -248.98K |
| Financing Cash Flow | 1.38B | 14.72M | 10.82M | -407.17K | -155.60K | 49.26M |
MiNK Therapeutics Technical Analysis
Positive
11.38
Price Trends
11.26
Positive
11.45
Positive
11.42
Positive
Market Momentum
0.18
Negative
53.44
Neutral
53.37
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For INKT, the sentiment is Positive. The current price of 11.38 is above the 20-day moving average (MA) of 11.33, above the 50-day MA of 11.26, and below the 200-day MA of 11.42, indicating a bullish trend. The MACD of 0.18 indicates Negative momentum. The RSI at 53.44 is Neutral, neither overbought nor oversold. The STOCH value of 53.37 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for INKT.
MiNK Therapeutics Risk Analysis
MiNK Therapeutics disclosed 76 risk factors in its most recent earnings report. MiNK Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
MiNK Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $60.16M | -4.89 | 83.45% | ― | ― | 15.65% | |
46 Neutral | $94.15M | -7.84 | 44.67% | ― | -96.72% | -253.97% | |
46 Neutral | $83.79M | -0.79 | -74.90% | ― | ― | 44.73% | |
46 Neutral | $53.10M | -1.76 | -39.76% | ― | ― | 65.39% | |
43 Neutral | $52.69M | -0.82 | -108.72% | ― | 2.15% | 17.34% | |
41 Neutral | $13.09M | -0.07 | -901.32% | ― | ― | 75.09% |
* Healthcare Sector Average
INKT
MiNK Therapeutics
11.43
-2.81
-19.75%
ATRA
Atara Biotherapeutics
9.20
-2.85
-23.65%
GTBP
GT Biopharma
0.30
-0.63
-67.88%
ACET
Adicet Bio
9.06
-2.46
-21.35%
TIL
Instil Bio
7.58
-19.42
-71.93%
TCRX
TScan Therapeutics
0.75
-1.05
-58.17%
MiNK Therapeutics Corporate Events
Executive/Board ChangesShareholder Meetings
MiNK Therapeutics Stockholders Back Directors, Ratify Auditor
Positive
Jun 23, 2026
MiNK Therapeutics held its Annual Meeting of Stockholders on June 17, 2026, with 3,277,906 shares, or 65.79% of eligible common stock, represented in person or by proxy, establishing a quorum for the session. Stockholders elected Class II director...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.